UPDATE: Baird Starts Taysha Gene Therapies (TSHA) at Outperform

March 8, 2022 4:24 PM EST
Get Alerts TSHA Hot Sheet
Price: $1.89 -7.8%

Rating Summary:
    13 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 6 | Down: 13 | New: 58
Join SI Premium – FREE
(Updated - March 9, 2022 6:38 AM EST)

Baird analyst Jack Allen initiates coverage on Taysha Gene Therapies (NASDAQ: TSHA) with a Outperform rating and a price target of $26.00.

The analyst comments "Taysha' lead asset, TSHA-120, is a gene therapy for giant axonal neuropathy (GAN). Given the combination of the encouraging clinical data from this program and high unmet need in GAN we believe this asset is well positioned to see a rapid regulatory approval pathway, with FDA guidance (expected mid-'22) representing the next key catalyst for the company. Additionally, data from four other programs including a planned study of TSHA-102 in Rett syndrome are also expected this year, providing Taysha a number of opportunities to spark investor enthusiasm."

For an analyst ratings summary and ratings history on Taysha Gene Therapies click here. For more ratings news on Taysha Gene Therapies click here.

Shares of Taysha Gene Therapies closed at $5.74 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities

Robert W Baird, FDA